Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756100 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL14067535 | 0.77 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL20033886 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL19086949 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL6623486 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL477109 | 0.76 | DYRK1A (0.53) | KDM4EALDH1A1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL16118521 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL16409613 | 0.76 | PIK3CG (0.40) | PIK3CGAKT1PIK3CAMTORAHR | |
| SCHEMBL12673757 | 0.76 | DYRK1A (0.41) | KDM4EALDH1A1SMN1; SMN2PIK3CGAKT1 | |
| SCHEMBL3357291 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4727938-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| CN-119841829-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025022093-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024259121-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2024-12-19 | — | — | WO | disclosed |
| US-20240124469-A1 | PIM KINASE INHIBITOR | HANGZHOU BIOSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-115135648-B | Dihydronaphthyridones, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4289847-A1 | PIM KINASE INHIBITOR | Hangzhou Biosun Pharmaceutical Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-11834467-B2 | Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors | 1ST Biotherapeutics, Inc. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | KDM4E 1547/4885ALDH1A1 353/4885SMN1; SMN2 2454/4885 |
| US-20240124469-A1 | PIM KINASE INHIBITOR | PIM1, PIM2, PIM3 | KDM4E 609/4885ALDH1A1 1562/4885SMN1; SMN2 3249/4885 |
| US-11834467-B2 | Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors | IP6K1, MCL1, HIPK1 | KDM4E 1596/4885ALDH1A1 1812/4885SMN1; SMN2 2500/4885 |
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | KDM4E 2514/4885ALDH1A1 3415/4885SMN1; SMN2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.